Oyster Point Pharma said yesterday that it raised $93 million in a Series B round to support the clinical development of its intranasal dry eye disease therapies.
The Princeton, N.J.-based company’s lead product candidates for dry eye disease are designed to stimulate the trigeminal parasympathetic pathway to trigger natural tear film production. The drugs, OC-01 and OC-02, are delivered using an ocular surface-sparing nasal spray.
Get the full story at our sister site, Drug Delivery Business News.
The post Oyster Point raises $93m for intranasal dry eye disease therapies appeared first on MassDevice.
from MassDevice https://ift.tt/2VkEkQc
Cap comentari:
Publica un comentari a l'entrada